MA30581B1 - Vaccin viral recombinant - Google Patents

Vaccin viral recombinant

Info

Publication number
MA30581B1
MA30581B1 MA31557A MA31557A MA30581B1 MA 30581 B1 MA30581 B1 MA 30581B1 MA 31557 A MA31557 A MA 31557A MA 31557 A MA31557 A MA 31557A MA 30581 B1 MA30581 B1 MA 30581B1
Authority
MA
Morocco
Prior art keywords
recombinant viral
viral vaccine
relates
present
viral vectors
Prior art date
Application number
MA31557A
Other languages
English (en)
Inventor
Jean-Yves Bonnefoy
Stephane Paul
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of MA30581B1 publication Critical patent/MA30581B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux vaccins viraux recombinants. En particulier, la présente invention concerne des produits combinés qui contiennent des vecteurs viraux recombinants et des composés spécifiques susceptibles d'améliorer la réponse immunitaire suscitée in vivo par lesdits vecteurs viraux recombinants.
MA31557A 2006-06-20 2009-01-09 Vaccin viral recombinant MA30581B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360028 2006-06-20
US85296406P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
MA30581B1 true MA30581B1 (fr) 2009-07-01

Family

ID=38657260

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31557A MA30581B1 (fr) 2006-06-20 2009-01-09 Vaccin viral recombinant

Country Status (15)

Country Link
US (1) US20100129403A1 (fr)
EP (1) EP2029169A2 (fr)
JP (1) JP2009541236A (fr)
KR (1) KR101141333B1 (fr)
CN (1) CN101472610A (fr)
AU (1) AU2007263281B2 (fr)
BR (1) BRPI0713711A2 (fr)
CA (1) CA2656266C (fr)
CR (1) CR10571A (fr)
IL (1) IL195683A0 (fr)
MA (1) MA30581B1 (fr)
MX (1) MX2008016036A (fr)
NO (1) NO20090194L (fr)
RU (1) RU2453335C2 (fr)
WO (1) WO2007147529A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2770075C (fr) 2009-08-07 2021-08-24 Perrine Martin Composition pour le traitement d'une infection par le virus de l'hepatite b
US9216213B2 (en) * 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045658A1 (fr) 2011-09-29 2013-04-04 Transgene Sa Composition et régime d'immunothérapie pour le traitement d'une infection par le virus de l'hépatite c
WO2013045668A2 (fr) 2011-09-29 2013-04-04 Transgene Sa Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c
EA029492B1 (ru) 2012-07-10 2018-04-30 Трансген Са Вакцина на основе микобактериальных антигенов
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
EP3092000A1 (fr) 2014-01-09 2016-11-16 Transgene SA Fusion d'antigènes mycobactériens hétérooligomères
PT3169341T (pt) 2014-07-16 2019-09-09 Transgene Sa Vírus oncolítico para a expressão de moduladores de pontos de controlo imunitário
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (fr) 2016-10-10 2018-04-19 Transgene Sa Polythérapie à base d'un produit immunothérapeutique et de modulateurs de mdsc
WO2018091680A1 (fr) 2016-11-18 2018-05-24 Transgene Sa Vecteurs oncolytiques à base de la variole bovine
CA3045228C (fr) 2016-12-28 2024-01-02 Transgene Sa Virus oncolytiques et molecules therapeutiques
WO2019020543A1 (fr) 2017-07-28 2019-01-31 Transgene Sa Virus oncolytiques exprimant des agents ciblant des modulateurs immunitaires métaboliques
WO2020011754A1 (fr) 2018-07-09 2020-01-16 Transgene Virus de la vaccine chimériques
CN114585376A (zh) 2019-08-29 2022-06-03 安斯泰来制药有限公司 基因工程改造的溶瘤痘苗病毒及其使用方法
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
WO2023213763A1 (fr) 2022-05-02 2023-11-09 Transgene Poxvirus codant pour un agent de liaison comprenant un sdab anti-pd-l1
WO2023213764A1 (fr) 2022-05-02 2023-11-09 Transgene Polypeptide de fusion comprenant un anti-pd-l1 sdab et un membre du tnfsf
WO2024003353A1 (fr) 2022-07-01 2024-01-04 Transgene Protéine de fusion comprenant une protéine d tensioactive et un élément de la tnfsf
WO2024038175A1 (fr) 2022-08-18 2024-02-22 Transgene Poxvirus chimériques

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0385630B1 (fr) 1989-02-27 1996-11-27 Riker Laboratories, Inc. 4-Amino-1H-imidazo(4,5-c)quinolines comme antiviraux
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
ATE247163T1 (de) 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1700603A3 (fr) 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Acides nucléiques immunostimulateurs
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
DK1335987T4 (en) 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
AU2002360278A1 (en) 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
CA2484049A1 (fr) * 2002-03-19 2003-10-02 Powdermed Limited Adjuvant pour vaccins
CA2551075A1 (fr) 2003-08-25 2005-03-03 3M Innovative Properties Company Combinaisons et traitements immunostimulatoires
WO2006042254A2 (fr) 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant pour vaccin a adn

Also Published As

Publication number Publication date
US20100129403A1 (en) 2010-05-27
EP2029169A2 (fr) 2009-03-04
MX2008016036A (es) 2009-04-07
CR10571A (es) 2009-05-14
WO2007147529A2 (fr) 2007-12-27
IL195683A0 (en) 2011-08-01
CA2656266A1 (fr) 2007-12-27
RU2453335C2 (ru) 2012-06-20
WO2007147529A3 (fr) 2008-02-28
JP2009541236A (ja) 2009-11-26
AU2007263281B2 (en) 2012-12-06
NO20090194L (no) 2009-03-10
AU2007263281A1 (en) 2007-12-27
BRPI0713711A2 (pt) 2012-10-30
KR101141333B1 (ko) 2012-05-23
RU2009101387A (ru) 2010-07-27
CA2656266C (fr) 2012-07-31
CN101472610A (zh) 2009-07-01
KR20090016719A (ko) 2009-02-17

Similar Documents

Publication Publication Date Title
MA30581B1 (fr) Vaccin viral recombinant
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
WO2009026465A3 (fr) Composition et procédés de fabrication et d'utilisation de protéines de la grippe
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
TW200806316A (en) Yeast-based vaccine for inducing an immune response
IL214460A0 (en) Malaria prime/boost vaccines
WO2009156405A8 (fr) Nouveaux composés immunoadjuvants à base de flagelline et leur utilisation
PL1881845T3 (pl) Szczepionki przeciwko wirusowi Nipah
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2006073431A3 (fr) Genes du virus de la fievre aphteuse exprimant des recombines avipox
EP1594536A4 (fr) Vaccin contre la grippe contenant un adjuvant
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MY169837A (en) Immunogenic compositions of staphylococcus aureus antigens
GB2386072A (en) Novel vaccine
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
WO2007008918A3 (fr) Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
MX2010006984A (es) Vacunas contra la malaria.
WO2008048344A3 (fr) Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes
GB2439259A (en) Vaccine against burkholderia infections
WO2007046839A3 (fr) Nouveaux vaccins a base de virus vivant